NASDAQ · BIVI
BioVie Inc.
$1.38-$0.08 (-5.48%)
BioVie Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.59% below the high.
Loading market information…
NASDAQ · GLMD · USD
Stock price, earnings
Quote as of Sep 9, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Galmed Pharmaceuticals Ltd.’s quoted price sits in the lower half of its reported 52-week range, 64.92% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Galmed Pharmaceuticals Ltd.’s next earnings report is currently expected on Nov 25, 2026, with estimated earnings per share of -$3.12. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Galmed Pharmaceuticals Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:42 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| -$0.62+30.34% vs estimate |
| $0.00-100.0% vs estimate |
| Q1 2025 | Apr 2, 2025 | -$1.94 | $1.64M |
|---|
| Q3 2024 | Nov 14, 2024 | -$2.31 | $0.00 |
|---|
THE ANALYST VIEW
16 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1.38-$0.08 (-5.48%)
BioVie Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.59% below the high.
$1.63+$0.03 (+1.61%)
InMed Pharmaceuticals Inc.’s quoted price sits in the upper half of its reported 52-week range, 30.26% below the high.
$0.19-$0.00 (-1.53%)
Theriva Biologics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 61.99% below the high.
$1.09-$0.01 (-0.91%)
Chemomab Therapeutics Ltd.’s quoted price sits in the lower half of its reported 52-week range, 66.25% below the high.
$2.64+$0.07 (+2.72%)
PMGC Holdings Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.82% below the high.
$0.79-$0.08 (-9.35%)
iSpecimen Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.6% below the high.
$1.32+$0.12 (+10.0%)
Virax Biolabs Group Limited’s quoted price sits in the lower half of its reported 52-week range, 93.93% below the high.
$0.01$0.00 (0.0%)
NKGen Biotech, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.56% below the high.
